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ABSTRACT There is limited knowledge on the yield of performing multiplex nucleic
acid testing (NAT) on multiple lower respiratory tract specimens from a single pa-
tient with a single instance of infection. We evaluated the performance characteris-
tics of multiplex NAT assays performed concurrently on bronchoalveolar lavage
(BAL) and bronchial wash (BW) specimens to detect respiratory pathogens. A retro-
spective study of admitted patients from March 2013 through December 2016 was
performed. Individual performance characteristics of BAL and BW specimens were
compared to positive results from either set of specimens. Only contemporaneous
BAL and BW specimens (received by the laboratory within 4 h of each other) were
included. The ﬁnal cohort included 170 patients, with 184 contemporaneous BAL
and BW specimens submitted for multiplex NAT (median age, 58 years; 62% male).
Of the patients with positive NAT results, 38 of 40 BW specimens tested positive
(overall percent agreement with combined testing, 98.9%; 95% conﬁdence interval
[CI], 95.5 to 98.9%), and 34 of 40 BAL specimens tested positive (overall percent
agreement with combined testing, 96.7%; 95% CI, 93.0 to 96.7%). Assays performed
on BW specimens identiﬁed 4 additional specimens and had a higher positive per-
cent agreement (95.0%) with combined testing results compared to those performed
on BAL specimens (85.0%). There was exact concordance in 174 specimens (94.6%;
negative and positive for respiratory pathogens, 144 and 34 specimens, respectively).
We observed high concordance (95%) between multiplex NAT results from contem-
poraneous BAL and BW specimens. Performance characteristics of BW specimen test-
ing were equivalent to those of BAL specimen testing. The beneﬁt of performing ad-
ditional testing should be carefully considered against the potential complications
and health care costs.
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Respiratory viruses are a common cause of upper respiratory tract infection and areresponsible annually for approximately 200 million cases of pneumonia worldwide
(1). Accurate diagnosis of respiratory viral pathogens is necessary to identify patients
who beneﬁt from speciﬁc treatments (such as antivirals), limit unnecessary antimicro-
bial use, and prevent nosocomial transmission by employing appropriate transmission-
based infection control precautions (1–7).
Previously, viruses were detected in respiratory specimens using direct ﬂuorescence
antibody assays, rapid antigen detection immunoassays, or viral culture. However,
studies have reported that these tests have low sensitivity (8–12). With the advent of
nucleic acid testing (NAT), the ability to diagnose respiratory viral infections and
characterize their epidemiology has greatly improved (13). A number of commercially
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available multiplex NAT assays have been developed to simultaneously detect multiple
respiratory pathogens within a single specimen.
The performance characteristics of various tests to detect respiratory pathogens
may differ based upon specimen type (14–16). For example, using older testing
methods, nasopharyngeal wash was superior to nasopharyngeal or oropharyngeal
swabs at detecting respiratory syncytial virus by indirect ﬂuorescent antibody test and
rapid enzyme immunoassay (16). More recent studies have compared multiplex NAT
results between nasopharyngeal versus bronchoalveolar lavage (BAL) specimens from
the same patient and obtained within 7 days (21, 22) or during the same procedure
(23). The reported concordance between assay results from nasopharyngeal and BAL
specimens in the above studies ranged from 77% to 89%. However, there is limited
knowledge on the relative performance characteristics of multiplex NAT for different
lower respiratory tract specimens, speciﬁcally for BAL versus bronchial wash specimens,
or whether target detection is improved when multiple lower respiratory tract speci-
mens are obtained from a single patient. These data have the potential to reduce health
care costs by eliminating unnecessary testing.
The purpose of this study is to compare the relative diagnostic yield of multiplex
NAT for respiratory viruses performed on bronchoalveolar lavage specimens versus
bronchial wash specimens.
MATERIALS AND METHODS
Setting. This was a retrospective cohort study. Using the hospital medical informatics database for
microbiological and clinical data, we evaluated all patients admitted to Barnes-Jewish Hospital (BJH), a
tertiary care academic medical center, from March 2013 through December 2016, who had a multiplex
NAT respiratory pathogen test performed on both BAL and bronchial wash specimen.
Multiplex NAT respiratory pathogen testing was implemented at BJH on 4 March 2013. The assay
used was the FilmArray respiratory panel (RP; BioFire Diagnostics, Salt Lake City, UT), used per the
manufacturer’s instruction. Respiratory viruses included on this panel include rhinovirus/enterovirus,
inﬂuenza (A, A/H1, A/H3, A/H1N1-2009, and B), parainﬂuenza, respiratory syncytial virus (RSV), human
metapneumovirus, coronavirus, and adenovirus. Results of tests for bacterial pathogens using this assay
were not evaluated in this study. Tests performed on nasopharyngeal, nasal wash, and sputum speci-
mens were not evaluated in this study.
Selection of study population. For each admitted patient, we matched multiplex NAT results from
BAL and bronchial wash specimens using specimen collection time. To account for potential clerical
differences in the time when specimens from the same procedure were collected, we deﬁned contem-
poraneous BAL and bronchial wash testing as specimens marked as being collected within 4 h of each
other (i.e., consistent with being obtained during a single bronchoscopy procedure). A pair of BAL and
bronchial wash specimens collected within 4 h of each other was considered a single observation for this
study. If a patient had multiple bronchoscopies during an admission in which contemporaneous BAL and
bronchial wash specimens were obtained and NAT was performed with each bronchoscopy, then each
pair of BAL and bronchial wash specimens was considered a distinct observation.
Bronchoalveolar lavage and bronchial washing. At our institution, a volume of 50- to 60-ml
aliquots of normal saline is instilled during bronchoscopy for BAL procedure. The saline is instilled only
after the bronchoscope is in a wedged position (i.e., cannot advance any further). This can be repeated
subsequently 2 to 3 times, with the total volume of instilled ﬂuid not exceeding 150 to 180 ml. The ﬁrst
50 to 60 ml of instilled saline is aspirated back into a container. If this ﬁrst aspirate is not discarded and
sent for testing, it is described as a “bronchial washing.” Most often the second (and sometimes third)
instilled saline aliquots, which are called BAL specimens, are aspirated and sent for the analysis.
Separate low-volume washes from a proximal airway, which are more commonly used for pulmonary
toileting, are excluded from the analysis (Fig. 1).
Statistical analyses. Patient demographics, ward location, length of hospital stay, comorbidities, and
discharge disposition were extracted from the hospital’s medical informatics database. The proportion of
positive tests was determined. Since there is no established gold standard, performance characteristics
of multiplex respiratory pathogen NAT on BAL or bronchial wash specimens were individually compared
with the combined positive test results for BAL or bronchial wash specimens (i.e., if either the BAL or
bronchial wash specimen was positive by NAT, then the combined test was considered positive), using
a 2  2 table. Overall agreement and percent positive and percent negative agreement with 95%
conﬁdence intervals were calculated (see http://statpages.info/ctab2x2.html). Data were analyzed using
SAS version 9.3 (SAS Institute, Cary, NC).
This study was approved by the Washington University Human Research Protection Ofﬁce with a
waiver of consent.
RESULTS
Study cohort. We identiﬁed 3,434 multiplex NAT respiratory pathogen tests per-
formed on BAL and bronchial wash specimens during the study period. Patients who
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had BAL and bronchial wash testing 4 h apart (n  304) and those who had testing
on BAL specimens only (n  2,124) or testing on bronchial wash specimens only (n 
331) were excluded. After exclusions, the ﬁnal study cohort included 184 paired BAL
and bronchial wash tests from 170 patients (Fig. 1). Nine patients (5.3%) had more than
one test per admission. The median age of the patients was 58 years, 62% were male,
and about 71% were white. A majority of the tests were performed within an intensive
care unit (ICU) (66.3%). Approximately 57% of patients had pneumonia, 37.5% had
acute respiratory failure, 34.2% had chronic obstructive pulmonary disease (COPD),
9.2% had acute bronchitis, and 1.6% had a history of lung transplant. A total of 40 of
184 (21.7%) bronchoscopy procedures resulted in a positive test result by BAL or
bronchial wash specimen (median age, 58; 57.5% male; 77.5% white; 45% of these tests
were performed within an ICU) (Table 1). Patients with a positive result were more likely
to be ICU patients. The most common respiratory pathogens recovered from either
specimen type were rhinovirus/enterovirus (20 of 40 patients [50.0%]), followed by
inﬂuenza A (7 of 40 patients [17.5%]) and coronavirus (4 of 40 patients [10.0%]).
Performance characteristics. Comparing individual specimen type results to com-
bined results for both specimens, 38 (95%) of the 40 patients with any positive
specimen had a positive bronchial wash specimen. The concordance of bronchial wash
results and combined specimen test results was 98.9% (95% conﬁdence interval [CI],
95.5 to 98.9%). A total of 34 (85%) patients with any positive specimen had a positive
BAL specimen. Percent agreement of BAL specimen tests with combined test results
was 96.7% (95% CI, 93.0 to 96.7%). Compared to BAL testing, bronchial wash testing
identiﬁed four additional positive specimens and had a signiﬁcantly higher positive
FIG 1 Study cohort. NAT, nucleic acid testing; RVP, respiratory virus pathogen; BAL, bronchoalveolar lavage; BW,
bronchial wash.
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percent agreement of 95.0% (95% CI, 87.1 to 95.0%) versus 85.0% for BAL testing (95%
CI, 76.3 to 85.0%) (Table 2).
There was concordance between bronchial wash and BAL test results in 174 (94.6%)
of the 184 specimen pairs. Of the 10 pairs with discordant test results, BAL tests were
negative in 6 specimens, whereas bronchial wash testing was positive for inﬂuenza A
in 1 specimen and for rhinovirus/enterovirus in 5 specimens. In 2 specimens, the
bronchial wash specimen test was negative, whereas the BAL specimen test was
positive (1 inﬂuenza A and 1 adenovirus). In the remaining two specimen, bronchial
TABLE 1 Demographic characteristics of 184 patients with contemporaneous, paired lower respiratory tract specimens tested by
multiplex nucleic acid test, by result for viral pathogena








Age in yrs (median, IQR) 58 (44–65) 58 (44–66) 58 (44–66) 0.692
Female gender 70 (38.0) 17 (42.5) 53 (36.8) 0.512
Race
White 130 (70.7) 31 (77.5) 99 (68.8) Ref
African American 42 (22.8) 9 (22.5) 33 (22.9) 0.747
Other 12 (6.5) 12 (8.3) 0.976
Location
ICU 122 (66.3) 18 (45.0) 104 (72.2) 0.011
Medicine 31 (16.8) 11 (27.5) 20 (13.9) Ref
Surgery 15 (8.2) 5 (12.5) 10 (6.9) 0.886
BMT/oncology 14 (7.6) 5 (12.5) 9 (6.3) 0.988
Cardiology 2 (1.1) 1 (2.5) 1 (0.7) 0.683
Length of hospital stay in days (median [IQR]) 18 (11–36) 20 (11–35) 18 (11–37) 0.612
Comorbidities
Pneumonia 105 (57.1) 25 (62.5) 80 (55.6) 0.433
Acute respiratory failure 69 (37.5) 19 (47.5) 50 (34.7) 0.14
Chronic obstructive pulmonary disease 63 (34.2) 13 (32.5) 50 (34.7) 0.793
Acute bronchitis 17 (9.2) 6 (15.0) 11 (7.6) 0.155
Acute respiratory distress syndrome 7 (3.8) 1 (2.5) 6 (4.2) 1.00
Acute respiratory infections 7 (3.8) 3 (7.5) 4 (2.8) 0.176
Lung transplant 3 (1.6) 3 (2.1)
Discharge status
Skilled nursing facility/other hospital 24 (13.1) 2 (5.0) 22 (15.3) Ref
Home 119 (64.7) 25 (62.5) 94 (65.3) 0.165
Expired 41 (22.3) 13 (32.5) 28 (19.4) 0.045
aStudy cohort included 184 paired BAL and bronchial wash tests from 170 unique patients. Each pair of BAL and bronchial wash specimens collected within 4 h of
each other was considered a single observation for this study. Demographic characteristics were reported for these 184 paired BAL and bronchial wash tests
(contemporaneous specimens).
bIQR, interquartile range; ICU, intensive care unit; BMT, bone marrow transplant. Values are reported as n (%) unless otherwise noted.
cRef, reference category.
TABLE 2 Comparison of multiplex nucleic acid test results by specimen type
Specimen type and resultsb
Bronchial wash or BAL specimen test






(95% CI)Positive (N  40) Negative (N  144)
Bronchial wash 98.9 (95.5–98.9) 95.0 (87.1–95.0) 100 (97.8–100)
Positive (n [%]) 38 (20.6) 0 (0.0)
Negative (n [%]) 2 (1.1) 144 (78.3)
BAL 96.7 (93.0–96.7) 85.0 (76.3–85.0) 100 (97.6–100)
Positive (n [%]) 34 (18.5) 0 (0.0)
Negative (n [%]) 6 (3.3) 144 (78.2)
aAny positive result noted for BAL and/or bronchial wash paired specimens was used as a gold standard.
bBAL, bronchoalveolar lavage; CI, conﬁdence interval.
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wash testing detected two pathogens (parainﬂuenza and rhinovirus/enterovirus for 1
specimen and coronavirus and rhinovirus/enterovirus for the other specimen), but the
BAL specimen was positive only for rhinovirus/enterovirus in either specimen (Table 3).
DISCUSSION
Accurate diagnosis of respiratory viral infections is necessary to identify patients
who might beneﬁt from speciﬁc treatments, such as antivirals, and to prevent noso-
comial spread using appropriate transmission-based infection control precautions (1–
7). Several studies have reported that multiplex NAT has a greater sensitivity than viral
cultures for diagnosing respiratory viral infections (17, 18). The diagnostic yield of
performing the multiplex NAT on multiple versus a single lower respiratory tract
specimen is not well studied. Performing multiple assays on respiratory specimens from
a single bronchoscopy may unnecessarily increase the cost of care. In our study, we
identiﬁed 95% concordance between multiplex NAT by bronchial wash specimen and
by BAL specimen for respiratory pathogens. Performance characteristics of testing by
bronchial wash specimen were comparable to those of testing of contemporaneously
obtained BAL specimens, identifying 4 additional patients in our cohort who were
positive for viral pathogens.
Bronchoalveolar lavage is associated with potential risks, such as worsening oxy-
genation and hemodynamic instability in critically ill patients (19, 20); therefore, any
additional beneﬁt of performing BAL should be carefully weighed against the potential
risk. In a recent study comparing the yield of BAL sample to that of nasopharyngeal (NP)
swab using the FilmArray respiratory panel, in 17 out of 86 patients (20%), BAL
identiﬁed pathogens that were not detected by NP swab. BAL was found to be useful
after a negative NP swab but did not add any new microbiological information once the
pathogen was identiﬁed by NP swab (21). Even in our study, although bronchial wash
specimen testing identiﬁed 4 additional patients positive for viral respiratory patho-
gens, BAL testing identiﬁed two specimen pairs with positive BAL specimens but
negative bronchial wash specimen, including one BAL specimen positive for inﬂuenza
A. While the cost and risk of bronchoscopy may not necessarily be averted by
equivalent detection of viruses in a bronchial wash (BW) specimen, studies should
consider optimization of viral pathogen detection, while reducing cost of testing.
Limitations of our study include its single-center retrospective design. We did not
conduct individual chart review for each patient. We did not have the data for
intubation. Therefore, we are unable to separate out bronchoscopic BAL done in
intubated patients versus nonintubated patients. We also did not have the ability to
perform additional testing to resolve discrepant results. We assumed BAL and bronchial
wash specimens with collection times documented within 4 h of each other to
represent specimens collected from a single procedure, which could have introduced
TABLE 3 Performance of bronchial wash versus BAL specimen multiplex nucleic acid test, by pathogena
Pathogen tested by
bronchial wash NAT
Pathogen tested by BAL NATb





None 144 1c 0 1c 0 0 0 0 146
Flu A 1c 5 0 0 0 0 0 0 6
RSV 0 0 1 0 0 0 0 0 1
Adenovirus 0 0 0 4 0 0 0 0 4
Coronavirus 0 0 0 0 4 0 0 1d 5
Metapneumovirus 0 0 0 0 0 1 0 0 1
Parainﬂuenza 0 0 0 0 0 0 2 1d 3
Rhinovirus/Enterovirus 5c 0 0 0 0 0 0 13 18
Total (BAL) 150 6 1 5 4 1 2 15 184
aThere were no inﬂuenza B viruses detected in the ﬁnal cohort. NAT, nucleic acid test; BAL, bronchoalveolar lavage; RSV, respiratory syncytial virus; Flu A, inﬂuenza A.
bNumbers in bold are concordant.
cDiscordant.
dPositive for different organisms. For two patients, bronchial washing testing detected two organisms (parainﬂuenza and rhinovirus/enterovirus for patient one and
coronavirus and rhinovirus/enterovirus for patient 2) but bronchoalveolar lavage testing identiﬁed only one organism (rhino/enterovirus for both patients).
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bias into our assessment. However, the majority of these specimens (82%; n 150) had
identical collection times, and 92% (n  169) of them had collection times within 30
min. Of the remaining 15 paired tests, 10 had collection times within 30 min to 2 h of
each other, and 5 specimens had recorded collection times greater than 2 h apart.
When we limited our analysis to only paired specimens collected within 30 min of each
other, the results were unchanged (data not shown). Due to lack of a comparator assay,
we used concordance and a positive result by either BAL or bronchial wash specimen
testing as the comparator for this analysis. Furthermore, we did not evaluate the
provider who performed the bronchoscopies, which may affect how each specimen
was collected. Since the main reason for BAL in patients with suspected infection is to
detect bacterial pathogens and not for viral detection, we compared the proportion of
BAL versus BW specimens from our ﬁnal cohort sent for additional testing for bacterial
pathogens (aerobic Gram-negative bacteria, Legionella spp., and Mycobacterium spp.)
and found no difference (data not shown). Strengths of our study include a large
sample size, evaluation of specimens obtained over multiple inﬂuenza seasons, and use
of a short window of comparison (4 h) in which the ability to detect virus is signiﬁcantly
higher.
In conclusion, our study shows that there is very high concordance between
multiplex NAT performed on bronchial wash and BAL specimens for suspected respi-
ratory virus infections. As the performance characteristics of bronchial wash specimens
were comparable to those of BAL specimens, in instances where BAL has a low return
volume, the ﬁrst-aliquot “bronchial washing” specimen can be considered for viral PCR
testing, while reducing the costs of multiple specimen testing. Future studies need to
evaluate this concordance in a larger patient population.
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